PF 5212377

Drug Profile

PF 5212377

Alternative Names: PF-05212377; PF-5212377; SAM-760; WYE-103760

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antidementias; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in France (PO, Capsule)
  • 28 Oct 2014 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Canada (PO)
  • 23 Oct 2014 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top